OVID Stock Analysis: Buy, Sell, or Hold?
OVID - Ovid Therapeutics Inc. Common Stock
$1.56
0.01 (0.65%)
▲
HOLD
LOW Confidence
Last Updated: January 30, 2026
Earnings: Mar 10, 2026
Get Alerted When OVID Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called OVID this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: OVID shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: OVID shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: OVID is currently trading at $1.56, which is considered oversold relative to its 30-day fair value range of $1.59 to $1.76.
Technical Outlook: Technically, OVID is in a strong uptrend. Immediate support is located at $1.48, while resistance sits at $1.84.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.05 (+161.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, OVID is in a strong uptrend. Immediate support is located at $1.48, while resistance sits at $1.84.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.05 (+161.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$1.59 -
$1.76
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
Protect Your Profits
Holding OVID? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 161.2% below Wall St target ($4.05)
- CAUTION: Recommendation downgraded due to -7.7% 5-day decline
Fair Price Analysis
30-Day Fair Range
$1.59 -
$1.76
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$1.48
Resistance Level
$1.84
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-4.17
Wall Street Target
$4.05
(+161.2%)
Revenue Growth (YoY)
-23.7%
Last updated: January 31, 2026 9:26 AM ET
Data refreshes hourly during market hours. Next update: 10:26 AM
Data refreshes hourly during market hours. Next update: 10:26 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OVID showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$22 | 60 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1035 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 57 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 60 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
Advanced OVID Option Strategies
Professional options setups generated by AI based on today's OVID price and gamma walls.
